Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a …
…, RJ Asghar, R Assadi, LS Atkins, C Atkinson… - The lancet, 2015 - thelancet.com
Background Up-to-date evidence about levels and trends in disease and injury incidence,
prevalence, and years lived with disability (YLDs) is an essential input into global, regional, …
prevalence, and years lived with disability (YLDs) is an essential input into global, regional, …
Potential mechanisms for achieving agricultural benefits from biochar application to temperate soils: a review
CJ Atkinson, JD Fitzgerald, NA Hipps - Plant and soil, 2010 - Springer
… (2007b) show evidence that the anthropogenic induced accumulation, via pyrolysis, of
highly refractory aryl-C structures was the most likely cause for the observed stability of SOC, at …
highly refractory aryl-C structures was the most likely cause for the observed stability of SOC, at …
Mechanism, specificity, and function of FANCD2‐FANCI ubiquitination and deubiquitination
… The C terminus of FANCE is disordered in the structure, and hence, only the N-terminal
part of FANCE (E NTD ) is shown. (D) FANCL RING binding to UBE2T’s core/UBC (ubiquitin-…
part of FANCE (E NTD ) is shown. (D) FANCL RING binding to UBE2T’s core/UBC (ubiquitin-…
A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for …
…, HR Anderson, KG Andrews, M Aryee, C Atkinson… - The lancet, 2012 - thelancet.com
Background Quantification of the disease burden caused by different risks informs
prevention by providing an account of health loss different to that provided by a disease-by-disease …
prevention by providing an account of health loss different to that provided by a disease-by-disease …
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
…, HR Anderson, LM Anderson, KG Andrews, C Atkinson… - The lancet, 2012 - thelancet.com
Background Measuring disease and injury burden in populations requires a composite metric
that captures both premature mortality and the prevalence and severity of ill-health. The …
that captures both premature mortality and the prevalence and severity of ill-health. The …
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
…, HR Anderson, LM Anderson, KG Andrews, C Atkinson… - The lancet, 2012 - thelancet.com
Background Non-fatal health outcomes from diseases and injuries are a crucial consideration
in the promotion and monitoring of individual and population health. The Global Burden of …
in the promotion and monitoring of individual and population health. The Global Burden of …
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010
…, HR Anderson, LM Anderson, KG Andrews, C Atkinson… - The lancet, 2012 - thelancet.com
Background Reliable and timely information on the leading causes of death in populations,
and how these are changing, is a crucial input into health policy debates. In the Global …
and how these are changing, is a crucial input into health policy debates. In the Global …
The state of US health, 1990-2010: burden of diseases, injuries, and risk factors
…, J Abraham, MK Ali, M Alvarado, C Atkinson… - Jama, 2013 - jamanetwork.com
Importance Understanding the major health problems in the United States and how they are
changing over time is critical for informing national health policy. Objectives To measure the …
changing over time is critical for informing national health policy. Objectives To measure the …
[BOOK][B] The decline of the West
O Spengler, A Helps, CF Atkinson - 1991 - books.google.com
… , prepared by the German scholar Helmut Werner, with the blessing of the Spengler estate,
consists of selections from the original (translated into English by Charles Francis Atkinson) …
consists of selections from the original (translated into English by Charles Francis Atkinson) …
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled …
…, IA McNeish, C Parkinson, M Powell, C Aghajanian… - The Lancet, 2017 - thelancet.com
Background Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-…
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-…